"Novo Nordisk Strikes Billion-Dollar Deals with Biotechs to Accelerate Obesity Drug Development"
Novo Nordisk is expanding its obesity treatment portfolio by partnering with two Flagship Pioneering startups, Omega Therapeutics and Cellarity, to develop an mRNA-based obesity drug and a new medication for metabolic-associated fatty liver disease (MASH), respectively. These collaborations mark the first initiatives under a partnership agreement between Flagship and Novo Nordisk established in 2022.